Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma To Invest More On NCD Partnerships Over Next Decade – IFPMA Report

This article was originally published in PharmAsia News

Executive Summary

Although Big Pharma is investing more in partnerships related to non-communicable diseases such as cancer and diabetes, gaps remain in tech transfer activities and local solutions in developing nations where NCDs are on the rise.

Advertisement

Related Content

Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases
GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC082234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel